Ferritin Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Ferritin Testing Market is projected to expand from USD 1.67 Billion in 2025 to USD 2.59 Billion by 2031, registering a CAGR of 7.59%. Ferritin testing serves as a critical clinical diagnostic method for quantifying serum ferritin levels, offering a definitive evaluation of total body iron reserves to identify conditions such as anemia or iron overload. The market is consistently driven by the rising incidence of nutritional deficiencies and the essential requirement for iron monitoring in the management of chronic diseases like renal failure. Data from the American Society of Hematology in 2024 indicates that the prevalence of iron deficiency among adolescent and young adult women in the United States could be as high as 39%, highlighting the substantial demand for diagnostic intervention.

Despite these strong growth factors, the market faces a major hurdle due to the high costs associated with the automated immunoassay systems needed for precise testing. This financial constraint, exacerbated by a lack of advanced laboratory infrastructure in emerging economies, restricts the availability of ferritin testing. Consequently, these economic and infrastructural barriers limit market accessibility in developing regions, constraining overall growth despite the clear clinical need for iron monitoring.

Market Drivers

The increasing global prevalence of iron deficiency anemia acts as a primary catalyst for market expansion, creating a pressing need for frequent diagnostic screening to avert long-term health complications. The gap between overt anemia and latent iron deficiency expands the target population for testing, encouraging the routine adoption of ferritin assays. A November 2025 systematic review by the American Society of Hematology revealed a pooled iron deficiency prevalence of 30% across various ferritin thresholds, suggesting a large, under-diagnosed patient pool. This figure, combined with 2024 data from the Centers for Disease Control and Prevention showing a 9.3% overall anemia prevalence in individuals aged two and older, reinforces the fundamental demand for hematological monitoring that supports the global market.

The rapidly growing geriatric population, which is susceptible to chronic ailments such as chronic kidney disease, further accelerates the demand for accurate ferritin monitoring. In elderly patients with complex comorbidities, distinguishing between iron deficiency anemia and anemia of chronic disease is vital for proper therapeutic action. A January 2025 study in the Nutrition Journal reported that 27.2% of non-dialysis chronic kidney disease patients had ferritin levels at or below 100 ng/mL, emphasizing the necessity for vigilant iron store evaluation in this demographic. As healthcare systems increasingly prioritize the management of chronic conditions to reduce hospital readmissions, the reliance on ferritin testing as a core diagnostic tool in geriatric care continues to intensify.

Market Challenges

The main impediment to the expansion of the Global Ferritin Testing Market is the prohibitive expense associated with automated immunoassay systems, compounded by a shortage of adequate laboratory infrastructure in developing regions. Precise ferritin measurement relies on advanced diagnostic platforms that require significant upfront capital investment and substantial ongoing operational funding. In emerging economies where healthcare budgets are often limited, this financial burden hinders the widespread installation of necessary equipment, creating an entry barrier that effectively excludes a large demographic of potential patients who require iron monitoring.

This economic strain is further intensified by the escalating costs of regulatory compliance and device maintenance, which manufacturers inevitably pass on to laboratories. Industry survey findings from MedTech Europe in 2025 project that manufacturers of in vitro diagnostics will face maintenance and re-certification costs that are 70% higher than initial certification fees over a standard cycle. These rising expenses increase the total cost of ownership for automated systems, making them financially unviable for resource-constrained facilities. Consequently, the market struggles to penetrate high-need developing nations, directly hampering global revenue growth despite the rising prevalence of iron deficiency.

Market Trends

The proliferation of at-home and self-testing kits is fundamentally reshaping the market by decentralizing diagnostic access and empowering patients to monitor iron stores without visiting clinical laboratories. This trend is largely supported by the growth of direct-to-consumer digital sales channels, which allow individuals to order and receive diagnostic kits directly, bypassing traditional healthcare bottlenecks. The convenience of capillary blood collection combined with digital result delivery appeals to health-conscious demographics, effectively circumventing the infrastructure limitations of centralized testing. For instance, Quest Diagnostics reported in their January 2025 financial results that their consumer-initiated platform had expanded to cover approximately 135 tests, including micronutrient deficiencies, thereby broadening access to essential metabolic monitoring.

Simultaneously, the integration of smartphone-based diagnostic platforms is revolutionizing the speed and affordability of ferritin quantification, particularly in resource-limited settings. By leveraging the high-resolution imaging capabilities of standard mobile devices, developers are creating colorimetric analysis tools that eliminate the need for expensive, stationary spectrophotometers. These portable solutions utilize custom applications to analyze reaction changes on microfluidic strips, offering immediate clinical data in non-laboratory environments. As highlighted by the Cornell Chronicle in December 2024, a smartphone-based diagnostic technology named AnemiaPhone was formally transferred to the Indian Council of Medical Research to enable rapid, point-of-need screening for iron deficiency, illustrating the scalability of mobile-linked diagnostics.

Key Players Profiled in the Ferritin Testing Market

• Eurolyser Diagnostica GmbH
• Cortez Diagnostics Inc.
• Thermo Fisher Scientific Inc.
• Biomerieux S.A
• Aviva Systems Biology Corporation
• Abnova Corporation
• CTK Biotech Inc.
• Randox Laboratories Ltd.
• Guangzhou Wondfo Biotech Co., Ltd.
• F. Hoffmann-La Roche Ltd.

Report Scope

In this report, the Global Ferritin Testing Market has been segmented into the following categories:

Ferritin Testing Market, by Product:

• Instrument
• Reagent
• Kits

Ferritin Testing Market, by Application:

• Anaemia
• Hemochromatosis
• Lead Poisoning
• Pregnancy
• Others

Ferritin Testing Market, by End Use:

• Hospitals
• Diagnostic Laboratories

Ferritin Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ferritin Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.